Neobe Therapeutics, a pioneering synthetic biology startup at the forefront of immuno-oncology innovation, is thrilled to announce the successful closure of a $2.34 million financing round.

Neobe has built a synthetic biology platform to engineer safe microbial strains to disrupt the microenvironment of solid tumours without affecting healthy tissues. Source: BIA News 29/2/2024